Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of PT003, PT005, and PT001 in COPD
NCT01085045Phase 2Completed
- Sponsor
- Pearl Therapeutics
- Start
- Mar 2010
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of glycopyrrolate metered dose inhaler and formoterol fumarate in chronic obstructive pulmonary disease (COPD) (8 arms), sponsored by Pearl Therapeutics. Primary endpoint: Forced Expiratory Volume in 1 Second Area Under the Curve 0-12 hours at Day 7. Started Mar 2010; status: completed.
02
Drugs
glycopyrrolate metered dose inhalerformoterol fumarate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01085045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01085045.